IP Library Granted Patent US 8,383,776
Granted Patent B2
US 8,383,776 · App. 12/838,593 · Granted Feb 26, 2013

Purification of factor XIII polypeptides from biological materials

Inventor: Susanne Bang (Bagsærd, DK)
Assignee: Novo Nordisk Health Care AG
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,383,776
App. No.
12/838,593
Granted
Feb 26, 2013
Kind
B2
Abstract

The invention relates to a method for purifying a factor XIII polypeptide from a biological material, the method comprising subjecting the material to sequential chromatography on an anion-exchange matrix and a hydrophobic interaction matrix.

Claims (8)

1. A method for purifying a factor XIII polypeptide from a biological material comprising subjecting the biological material to sequential chromatography on an anion-exchange matrix and a hydrophobic interaction matrix wherein no precipitation step to produce a factor XIII polypeptide-containing precipitate is performed, and wherein chromatography on an anion-exchange matrix is performed with a stabilizing agent selected from the group consisting of propylene glycol, propan-1,3-diol, propyl alcohol, and isopropyl alcohol.

2. A method according to claim 1 , wherein the factor XIII polypeptide is a recombinant factor XIII.

3. A method according to claim 2 , wherein the factor XIII polypeptide is human factor XIII.

4. A method according to claim 2 , wherein the factor XIII polypeptide is a dimer of A subunits.

5. A method according to claim 4 , wherein the factor XIII polypeptide is a dimer of human A subunits.

6. A method according to claim 1 , wherein the biological material is a biological fluid.

7. A method according to claim 6 , wherein the biological fluid is the supernatant of a cell lysate.

8. A method according to claim 7 , wherein the biological fluid is the supernatant of a yeast cell lysate.

Assignments (2)
CHANGE OF ADDRESS OF ASSIGNEE Recorded Nov 15, 2021
From: NOVO NORDISK HEALTHCARE A/G
To: NOVO NORDISK HEALTHCARE AG
Reel/Frame 058122/0546 →
CHANGE OF ADDRESS Recorded Jun 19, 2013
From: NOVO NORDISK HEALTHCARE A/G
To: NOVO NORDISK HEALTHCARE AG
Reel/Frame 030653/0189 →
Priority Claims (1)
DK 2004 01301 · Aug 27, 2004 · national
Continuity (3)
Continuation 11661524
Provisional Application 60606026 · Aug 31, 2004
Related Publication 20100297098A1 · Nov 25, 2010